170 related articles for article (PubMed ID: 21156818)
1. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
Siegel D; Shieh B; Yan C; Kepa JK; Ross D
J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
[TBL] [Abstract][Full Text] [Related]
2. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
3. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Mol Pharmacol; 2006 Oct; 70(4):1194-203. PubMed ID: 16825487
[TBL] [Abstract][Full Text] [Related]
4. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation.
Guo W; Siegel D; Ross D
J Pharm Sci; 2008 Dec; 97(12):5147-57. PubMed ID: 18393300
[TBL] [Abstract][Full Text] [Related]
5. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
6. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
Douglas M; Lim AR; Porter JR; West K; Pink MM; Ge J; Wylie AA; Tibbits TT; Biggs K; Curtis M; Palombella VJ; Adams J; Fritz CC; Normant E
Mol Cancer Ther; 2009 Dec; 8(12):3369-78. PubMed ID: 19952119
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P
Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114
[TBL] [Abstract][Full Text] [Related]
8. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
[TBL] [Abstract][Full Text] [Related]
9. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG.
Hadley KE; Hendricks DT
BMC Cancer; 2014 May; 14():334. PubMed ID: 24886060
[TBL] [Abstract][Full Text] [Related]
10. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Maloney A; Clarke PA; Naaby-Hansen S; Stein R; Koopman JO; Akpan A; Yang A; Zvelebil M; Cramer R; Stimson L; Aherne W; Banerji U; Judson I; Sharp S; Powers M; deBilly E; Salmons J; Walton M; Burlingame A; Waterfield M; Workman P
Cancer Res; 2007 Apr; 67(7):3239-53. PubMed ID: 17409432
[TBL] [Abstract][Full Text] [Related]
11. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Fujii Y; Kato T; Kubota N; Fujimori A; Niwa O; Okayasu R
Oncol Rep; 2010 Jan; 23(1):199-203. PubMed ID: 19956882
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.
Guo W; Reigan P; Siegel D; Ross D
Drug Metab Dispos; 2008 Oct; 36(10):2050-7. PubMed ID: 18635747
[TBL] [Abstract][Full Text] [Related]
13. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
[TBL] [Abstract][Full Text] [Related]
14. Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas.
Singh A; Singh A; Sand JM; Bauer SJ; Hafeez BB; Meske L; Verma AK
J Invest Dermatol; 2015 Apr; 135(4):1098-1107. PubMed ID: 25337691
[TBL] [Abstract][Full Text] [Related]
15. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
Siegel D; Gustafson DL; Dehn DL; Han JY; Boonchoong P; Berliner LJ; Ross D
Mol Pharmacol; 2004 May; 65(5):1238-47. PubMed ID: 15102952
[TBL] [Abstract][Full Text] [Related]
16. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins.
Reigan P; Siegel D; Guo W; Ross D
Mol Pharmacol; 2011 May; 79(5):823-32. PubMed ID: 21285336
[TBL] [Abstract][Full Text] [Related]
17. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
[TBL] [Abstract][Full Text] [Related]
18. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-β type II receptor.
Noh H; Kim HJ; Yu MR; Kim WY; Kim J; Ryu JH; Kwon SH; Jeon JS; Han DC; Ziyadeh F
Lab Invest; 2012 Nov; 92(11):1583-96. PubMed ID: 22964853
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]